泛KRAS抑制剂使瘤信号和瘤生长失效
Dongsung Kim1,2, Lorenz Herdeis3, Dorothea Rudolph3
1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
研究人员发现了一种新的非共价抑制剂,该抑制剂向KRAS蛋白的非活性形式,包括常见的癌症突变. 这种泛KRAS抑制剂有望通过阻断瘤生长而不会损害健康细胞来治疗各种KRAS驱动的癌症.
科学领域:
- 癌症学
- 分子生物学
- 药物发现
背景情况:
- 在许多癌症中,KRAS突变很普遍,导致瘤生长.
- 目前的治疗主要针对KRAS G12C突变.
- 针对其他KRAS突变和野生类型的KRAS仍然是一个挑战.
研究的目的:
- 发现和描述一种针对KRAS非活性状态的新型非共价抑制剂.
- 评估该抑制剂对KRAS与NRAS和HRAS的选择性.
- 在临床前模型中评估这种泛KRAS抑制剂的治疗潜力.
主要方法:
- 在选和生物化学测试中识别和描述抑制剂.
- 基于细胞的测定以评估KRAS信号和扩散的抑制.
- 使用KRAS突变癌症小鼠模型的体内研究.
主要成果:
- 鉴定出一种非共价抑制剂,它能以高亲和力结合KRAS的非活性形式.
- 这种抑制剂对KRAS具有选择性,不影响NRAS和HRAS.
- 它有效地阻断了核酸交换,抑制了野生型KRAS和广泛的KRAS突变.
- 抑制下游信号传递和扩散是KRAS突变癌细胞的特征.
- 在患有KRAS突变癌症的小鼠中抑制了瘤生长,没有显著的不良影响.
结论:
- 大多数KRAS基蛋白依赖于核酸交换来激活和在活性和非活性状态之间循环.
- 一种新的非共价抑制剂为广泛的KRAS驱动癌症提供了潜在的治疗策略.
- 泛KRAS抑制剂在癌症治疗方面需要进一步的临床研究.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Inhibition of Cdk Activity
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The Ras Gene
Ras is a...
PI3K/mTOR/AKT Signaling Pathway
Mitogens and the Cell Cycle
